ISSN (Print): 2328-3947

ISSN (Online): 2328-3955

Editor-in-Chief: Hari K. Koul




Highly Conserved Epitopes of ZIKA Envelope Glycoprotein May Act as a Novel Peptide Vaccine with High Coverage: Immunoinformatics Approach

1Department of Biotechnology, Africa city of Technology- Khartoum, Sudan

2Al Neelain University, Faculty of Medical Laboratory Sciences

3Department of Microbiology, Soba University Hospital, Khartoum-Sudan

American Journal of Biomedical Research. 2016, 4(3), 46-60
doi: 10.12691/ajbr-4-3-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Marwan Mustafa Badawi, Marwa Mohamed Osman, Afra AbdElhamid Fadl Alla, Ammar Mohammed Ahmedani, Mohamed hamed Abdalla, Mosab Mohamed Gasemelseed, Ahmed Abubakar Elsayed, Mohamed Ahmed Salih. Highly Conserved Epitopes of ZIKA Envelope Glycoprotein May Act as a Novel Peptide Vaccine with High Coverage: Immunoinformatics Approach. American Journal of Biomedical Research. 2016; 4(3):46-60. doi: 10.12691/ajbr-4-3-1.

Correspondence to: Marwan  Mustafa Badawi, Department of Biotechnology, Africa city of Technology- Khartoum, Sudan. Email:


Zika virus (ZIKV) is positive sense single stranded RNA of Flavivirus genus belonging to the Flaviviridae family. It has neither drug nor protective vaccine, and considered to be in relatedness to neurological abnormalities such as Guillain Barre Syndrome and microcephaly of neonates. The aim of this study is to analyze envelope glycoprotein E of all Zika strains using in silico approaches looking for conservancy, which is further studied to predict all potential epitopes that can be used after in vitro and in vivo confirmation as a therapeutic peptide vaccine. A total of 50 Zikavirusvariants’(include 12from South America) polyproteins retrieved from NCBI database were aligned, and the conserved regions of Envelope Glycoprotein-E were selected for epitopes prediction. IEDB analysis resource was used to predict B and T cell epitopes and to calculate the population coverage. Epitopes with high scores in both B cell and T cell epitopes predicting tools were suggested. Three epitopes were proposed for international therapeutic peptide vaccine for B cell (AQDKP, TPNSPRAE and TPHWNNK) and two other epitopes designed especially for South America strains (LDKQSDTQYV and EVQYAGTDGPCK). For T cell epitopes, MMLELDPPF epitope was highly recommended as therapeutic peptide vaccine to interact with MHC class I along with three other epitopes (MAVLGDTAW, KEWFHDIPL and DTAWDFGSV) which showed very good population coverage against the whole world population. Three epitopes showed high affinity to interact with MHC class II alleles (FKSLFGGMS, LITANPVIT and VHTALAGAL) with excellent population coverage throughout the world and South America region. Herd immunity protocols can be achieved in countries with low population coverage percentage to minimize the active transmission of the virus, especially among pregnant women and other groups at risk.We recommendin vitro and in vivo proving the effectiveness of these proposed epitopes as a vaccine, as well as to be used as a diagnostic screening test.



[1]  Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952; 46(5): 509-20.
[2]  Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009; 15(9): 1347-50.
[3]  Robert S. Lanciotti, Olga L. Kosoy, Janeen J. Laven, Jason O. Velez, Amy J. Lambert, Alison J. Johnson, Stephanie M. Stanfi eld, and Mark R. Duffy. Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State,Micronesia, 2007.Emerging Infectious Diseases. 2008; 14 (8): 1232-39.
[4]  Dick GW. Zika virus pathogenicity and physical properties. Trans R Soc Trop Med Hyg. 1952; 46: 521-34.
[5]  Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360: 2536-2543.
Show More References
[6]  Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, et al. Probable nonvector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis. 2011; 17(5): 880-2.
[7]  World Health Organization. ZIKA VIRUS MICROCEPHALY AND GUILLAIN-BARRÉ SYNDROME. 2016. Available at:
[8]  World Health Organization. ZIKA SITUATION REPORT. 2016. Print.
[9]  Charrel RN, Leparc-Goffart I, Pas S, de Lamballerie X, Koopmans M & Reusken C. State of knowledge on Zika virus for an adequate laboratory response [Submitted]. Bull World Health Organ E-pub: 10 Feb 2016.
[10]  Services YSDoH. Zika virus. Information for clinicians and other health professionals. Federated States of Micronesia: Yap State Department of Health; 2007. p. 2.
[11]  Cerdeño-Tárraga AM, Efstratiou A, Dover LG, et al. The complete genome sequence and analysis of Corynebacterium diphtheriaeNCTC13129. Nucleic Acids Research. 2003; 31(22): 6516-6523.
[12]  Trent DW, Qureshi AA. Structural and nonstructural proteins of Saint Louis encephalitis virus. Journal of Virology. 1971; 7(3):379-88.
[13]  Global Research Collaboration for Infectious Disease Preparedness,. Zika Virus (ZIKV) Outbreak. 2015. Print.
[14]  Rezaul Islam, M Sadman Sakib & Aubhishek Zaman. A computational assay to design an epitope- based peptide vaccine against chokungunya virus. Future virol.2012 7(10): 1029-1042.
[15]  Arafat Rahman Oany, Tahmina Sharmin,Afrin Sultana Chowdhury,Tahmina Pervin Jyot and Md Anayet Hasan. Highly Conserved Reagions in Ebola Virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approach.Oany etal, In Silico Pharmacology(2015) 3:7.
[16]  Anayet Hasan, Mehjabeen Hossain and Md. Jibran Alam. A Computational Assay to Design an Epitope-Based Peptide Vaccine Against Saint Louis Encephalitis Virus. Bioinformatics and Biology Insights 2013:7 347-355.
[17]  Jens Erik Pontoppidan Larsen, Ole Lund and Morten Nielsen. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2: 2.
[18]  Emini EA, Hughes JV, Perlow DS, Boger J. 1985. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55:836-839.
[19]  Kolaskar AS, Tongaonkar PC. 1990. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett276:172-174.
[20]  Parker JM, Guo D, Hodges RS. 1986. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25:5425-5432.
[21]  Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette A, Lund O, Bourne PE, Nielsen M, Peters B. 2012. Immune epitope database analysis resource. NAR.
[22]  Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, Brunak S, Lund O. 2003. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12:1007-1017.
[23]  Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, and Nielsen M. 2008. NetMHC-3.0: Accurate web accessible predictions of Human, Mouse, and Monkey MHC class I affinities for peptides of length 8-11. NAR 36:W509-512.
[24]  Peters B, Sette A. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6:132.
[25]  Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, Peters B. 2008. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 4:2.
[26]  Kim Y, Ponomarenko J, Zhu Z, et al. Immune epitope database analysis resource. Nucleic Acids Research. 2012;40(Web Server issue):W525-W530.
[27]  Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 4(4):e1000048.
[28]  Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. 2010. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 11:568.
[29]  Pratik Narain Srivastava, Richa Jain, Shyam Dhar Dubey, Sharad Bhatnagar, Nabeel Ahmad. Prediction of Epitope-Based Peptides for Vaccine Development from Coat Proteins GP2 and VP24 of Ebola Virus Using Immunoinformatics, International Journal of Peptide Research and Therapeutics (2016) 22:119-133.
[30]  Zhang, Q., Wang, P., Kim, Y., Haste-Andersen, P., Beaver, J., Bourne, P. E. et al. (2008). Immune epitope database analysis resource (IEDB-AR).Nucleic Acids Research36(Web Server issue), W513-W518.
[31]  Bui HH,Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006 Mar 17;7:153.
[32]  The Phyre2 web portal for protein modeling, prediction and analysis Kelley LA et al. Nature Protocols 10, 845-858 (2015).
[33]  UCSF Chimera--a visualization system for exploratory research and analysis. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. J Comput Chem. 2004 Oct;25(13):1605-12.
[34]  Bachler, B.C.; Humbert, M.; Palikuqi, B.; Siddappa, N.B.; Lakhashe, S.K.; Rasmussen, R.A.; Ruprecht, R.M. Novel biopanning strategy to identify epitopes associated with vaccine protection. J. Virol. 2013, 87, 4403-4416.
[35]  Perrie, Y.; Kirby, D.; Bramwell, V.W.; Mohammed, A.R. Recent developments in particulate-based vaccines. Recent Pat. Drug Deliv. Formul. 2007, 1, 117-129.
[36]  Black, M.; Trent, A.; Tirrell, M.; Olive, C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev. Vaccines 2010, 9, 157-173.
[37]  Thompson, A.L.; Staats, H.F. Cytokines: The future of intranasal vaccine adjuvants. Clin. Dev. Immunol. 2011.
[38]  Petrovsky, N.; Aguilar, J.C. Vaccine adjuvants: Current state and future trends. Immunol. Cell Biol. 2004, 82, 488-496.
[39]  Sesardic, D. Synthetic peptide vaccines. J. Med. Microbiol. 1993, 39, 241-242.
[40]  Liu, Y.; McNevin, J.; Zhao, H.; Tebit, D.M.; Troyer, R.M.; McSweyn, M.; Ghosh, A.K.; Shriner, D.; Arts, E.J.; McElrath, M.J.; et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: Fitness-balanced escape. J. Virol. 2007, 81, 12179-12188.
[41]  Kolesanova, E.F.; Sanzhakov, M.A.; Kharybin, O.N. Development of the schedule for multiple parallel ―difficult Peptide synthesis on pins. Int. J. Pept. 2013.
[42]  Epstein, J.E.; Giersing, B.; Mullen, G.; Moorthy, V.; Richie, T.L. Malaria vaccines: Are we getting closer? Curr. Opin. Mol. Ther. 2007, 9, 12-24.
[43]  Volpina, O.M.; Gelfanov, V.M.; Yarov, A.V.; Surovoy, A.Y.; Chepurkin, A.V.; Ivanov, V.T. New virus-specific T-helper epitopes of foot-and-mouth disease viral VP1 protein. FEBS Lett. 1993, 333, 175-178.
[44]  Tarradas, J.; Monso, M.; Munoz, M.; Rosell, R.; Fraile, L.; Frías, M.T.; Domingo, M.; Andreu, D.; Sobrino, F.; Ganges, L. Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs. Vaccine 2011, 29, 4422-4429.
[45]  Stanekova, Z.; Kiraly, J.; Stropkovska, A.; Mikušková, T.; Mucha, V.; Kostolanský, F.; Varečková, E. Heterosubtypic protective immunity against influenza a virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol. 2011, 55, 61-67.
[46]  Oscherwitz, J.; Yu, F.; Cease, K.B. A synthetic peptide vaccine directed against the 2ss2–2ss3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J. Immunol. 2010, 185, 3661-3668.
[47]  Solares, A.M.; Baladron, I.; Ramos, T.; Valenzuela, C.; Borbon, Z.; Fanjull, S.; Gonzalez, L.; Castillo, D.; Esmir, J.; Granadillo, M.; et al. Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial. ISRN Obstet. Gynecol. 2011.
[48]  Bernhardt, S.L.; Gjertsen, M.K.; Trachsel, S.; Møller, M.; Eriksen, J.A.; Meo, M.; Buanes, T.; Gaudernack, G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br. J. Cancer 2006, 95, 1474-1482.
[49]  Brunsvig, P.F.; Aamdal, S.; Gjertsen, M.K.; Kvalheim, G.; Markowski-Grimsrud, C.J.; Sve, I.; Dyrhaug, M.; Trachsel, S.; Møller, M.; Eriksen, J.A.; et al. Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006, 55, 1553-1564.
[50]  Brunsvig, P.F.; Kyte, J.A.; Kersten, C.; Sundstrøm, S.; Møller, M.; Nyakas, M.; Hansen, G.L.; Gaudernack, G.; Aamdal, S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 2011, 17, 6847-6857.
[51]  Kyte, J.A.; Gaudernack, G.; Dueland, S.; Trachsel, S.; Julsrud, L.; Aamdal, S. Telomerase peptide vaccination combined with temozolomide: A clinical trial in stage IV melanoma patients. Clin. Cancer Res. 2011, 17, 4568-4580.
[52]  Greten, T.F.; Forner, A.; Korangy, F.; N’Kontchou, G.; Barget, N.; Ayuso, C.; Ormandy, L.A.; Manns, M.P.; Beaugrand, M.; Bruix, J. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010, 10, e209.
[53]  Kyte, J.A.; Trachsel, S.; Risberg, B.; Thor, S.P.; Lislerud, K.; Gaudernack, G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol. Immunother. 2009, 58, 1609-1626. 25.
[54]  Mohammad Mahfuz Ali Khan Shawan, Hafij Al Mahmud, Md. Mahmudul Hasan, Afroza Parvin, Md. Nazibur Rahman and S. M. Badier Rahman. In Silico Modeling and Immunoinformatics Probing Disclose the Epitope Based PeptideVaccine Against Zika Virus Envelope Glycoprotein. Indian J. Pharm. Biol. Res. 2014; 2(4):44-57.
[55]  Andrea J. Sant and Andrew McMichael. Revealing the role of CD4+ T cells in viral immunity. Journal of Experimental Medicine. 2012; 209(8): 1391-1395.
[56]  Paul S1, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptide binding repertoires of different size, affinity and immunogenicity. Journal of Immunology. 2013; 191(12):5831-9.
[57]  A. Arnaiz-Villena, J. Moscoso, J.I. Serrano-Vela, J. Martinez-Laso. The uniqueness of amerindians according to HLA genes and the peopling of the Americas. Journal of Inmunología. 2006; 25: 13-24.
[58]  Lizcano Fernández, Francisco “Composición Étnica de las Tres Áreas Culturales del Continente Americano al Comienzo del Siglo XXI”.Convergencia (in Spanish) (Mexico: Universidad Autónoma del Estado de México, Centro de Investigación en Ciencias Sociales y Humanidades). 2005; 38: 185-232.
[59]  Zika virus infection outbreak, Brazil and the Pacific region”. Stockholm: European Centre for Disease Prevention and Control. 25 May 2015. p. 4. Retrieved 12 February 2016.
[60]  Testa, J.S.; Philip, R. Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol. 2012, 7, 1077-1088. 28. Lanier, J.G.; Newman, M.J.; Lee, E.M.;
[61]  Sette, A.; Ahmed, R. Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses. Vaccine 1999, 18, 549-557.
Show Less References


Computational Analysis of Single Nucleotide Polymorphism (SNPs) in Human GRM4 Gene

1Department of Bioinformatics, Africa city of technology, Sudan

2Alneelain University Faculty of Medical Laboratory Sciences, Sudan

3Department of haeatology, Elnehoud teaching Hospital, Sudan

4Medical Lab Manager, Tyba Hospital, Sudan

5Institute of Endemic Diseases, Khartoum University, Sudan

6Head Department of Biotechnology, Biotechnology Park, Africa city of technology, Sudan

American Journal of Biomedical Research. 2016, 4(3), 61-73
doi: 10.12691/ajbr-4-3-2
Copyright © 2016 Science and Education Publishing

Cite this paper:
Afra Abd Elhamid Fadlalla Elshaikh, Mosab Mohamed Ismaiel, Marwa Mohamed Osman, Samah Ahmed Ibrahim Shokri, Samia Othman massad, Nahid Ebrahim Merghani Fadl, Arafa Habiballa Ibrahim, Selma Shiekh Idris, Maab Mohamed Abdalla, Mohamed Ahmed Salih. Computational Analysis of Single Nucleotide Polymorphism (SNPs) in Human GRM4 Gene. American Journal of Biomedical Research. 2016; 4(3):61-73. doi: 10.12691/ajbr-4-3-2.

Correspondence to: Afra  Abd Elhamid Fadlalla Elshaikh, Department of Bioinformatics, Africa city of technology, Sudan. Email:


Background: L-glutamate is one of the most common amino acid in nature and it acts as excitatory neurotransmitter in the central nervous system. GRM4 is a large gene located in chromosome 6 and consists of 7217 bp (NCBI) divided into 10 exons. The location of GRM4 (chromosomal segment 6p21.3) is tentative susceptibility loci for Juvenile Myoclonic Epilepsy so many studies investigate the association of GRM4 polymorphism with myoclonic epilepsy juvenile. Design and methods: GRM4 gene was investigated in dbSNP/NCBI database NCBI and we used computational analysis approach. Deleterious nsSNPs were predicted by SIFT and Polyphen soft wares then the damaging nsSNPs were submitted to I mutant tool. Protein structural analysis of amino acid variants was performed by Chimera 1.8 and Project Hope. Results: We analyze 29854 SNPs from NCBI; 8561 of them found on homosapiens; of which 330 were missense, of which 208 were in the coding region, 334 were non-synonymous SNPs (nsSNPs), 232 were in the 3'un-translated region. These SNPs were analyzed using different soft wares; SIFT, Polyphen-2, Imutant3.0, PhD-SNP, PolymiRTs, Project Hope and GENEMAIA to investigate the effect of SNPs mutations on GRM4 protein structure and function. Conclusions: Computational tools were used to analyze deleterious SNPs in GRM4 gene. Out of 8561 SNPs, the SNPs (rs184636998), (rs199744441), (rs199744441), (rs149277708), (rs144660534), (rs139236496) were identified as highly damaging in coding region confirmed by using bioinformatics tools . In 3'un-translated region two SNPs (rs188406833) and (rs192860479) contained (C) allele had 4 miRSite as target binding site can be disrupts a conserved miRNA and one SNPs (rs77415386) contained (D) allele had 6 miRSite as derived allele that disrupts a conserved miRNA site. Further study must be done to detect the effect of these SNPs on the protein structure and function.



[1]  Bao L, Zhou M, Wu L, Lu L, Goldowitz D, Williams RW, Cui Y. PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. J Nucleic Acids Res (2007); 35: 1-4.
[2]  Capriotti E., Calabrese R. and Casadio R.. Predicting the insurgence of human genetic disease associated to single point protein mutation with Support Vector Machines and evolutionary information.. Bioinformatics.2006 ; 22: 2729-2734.
[3]  C.N. Pauline, H. Steven. SIFT: predicting amino acid changes that affect protein function. J Nucleic Acids Res (2003); 31: 3812-3814.
[4]  E. Capriotti, P. Fariselli, R. Casadio. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. J Nucleic Acid Res (2005); 33:306-310.
[5]  Goddard TD1, Huang CC, Ferrin. TE Software extensions to UCSF chimera for interactive visualization of large molecular assemblies. J Structure (2005); 13(3):473-82.
Show More References
[6]  González-Pérez A1, López-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. J Am Hum Genet (2011); 88: 440-449.
[9]  Makoff A, Lelchuk R, Oxer M, Harrington K, Emson P. Molecular characterization and localization of human metabotropic glutamate receptor type 4 .J Brain Research. Molecular Brain Research (1996); 37 (1-2): 239-48.
[10]  Muhle H1, von Spiczak S, Gaus V, Kara S, Helbig I, Hampe J, Franke A, Weber Y, Lerche H, Kleefuss-Lie AA, Elger CE, Schreiber S, Stephani U, Sander T. Role of GRM4 in idiopathic generalized epilepsies analysed by genetic association and sequence analysis. J Epilepsy Res (2010);89(2-3):319-26.
[11]  Venselaar, H., T. A. te Beek, R. K. Kuipers, M. L. Hekkelman and G. Vriend. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. J BMC bioinformatics (2010); 11(1): 548.
[12]  Warde-Farley D1, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, Morris Q. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. J Nucleic Acids Res (2010); 38:214-20.
[13]  Wong CG1, Scherer SW, Snead OC 3rd, Hampson DR. Localization of the human mGluR4 gene within an epilepsy susceptibility locus. J Brain Res Mol Brain Res (2001); 19 (1): 109-16.
[14]  Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR, Johnson BG, Schoepp DD, Belagaje RM. Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. J Brain Research. Molecular Brain Research (1998); 53 (1-2): 88-97.
Show Less References


Methylenetetrahydrofolate Reductase C677T and Platelet Glycoprotein IIb/IIIa Genes Polymorphism in Myocardial Infarction Egyptian Patients

1Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egyp

2Cardiology Departments, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

American Journal of Biomedical Research. 2016, 4(3), 74-79
doi: 10.12691/ajbr-4-3-3
Copyright © 2016 Science and Education Publishing

Cite this paper:
Kefah H Ali, Nagwan A Sabek, Loaa A Tag Eldeen, Emad F Ismail, Gamela Nasr. Methylenetetrahydrofolate Reductase C677T and Platelet Glycoprotein IIb/IIIa Genes Polymorphism in Myocardial Infarction Egyptian Patients. American Journal of Biomedical Research. 2016; 4(3):74-79. doi: 10.12691/ajbr-4-3-3.

Correspondence to: Nagwan  A Sabek, Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egyp. Email:


Background: Hyperhomocysteinemia and platelet glycoprotein GpIIIa polymorphism had been identified as risk factors for coronary atherosclerosis. The methylenetetrahydrofolate reductase MTHFR C677T variant has been shown to influence homocysteine metabolism, the interaction of plasma tHcy with other conventional risk factors remain uncertain in the clinical setting of acute myocardial infarction (AMI). The present study aimed to examine whether the MTHFR and platelet glycoprotein IIIa polymorphisms were associated with increased risk of (MI) in Egyptian patients. Subjects and Method: 150 newly diagnosed MI patients and 50 healthy matched subjects were recruited into this study, genotyping of the MTHFR C677T and GpIIIa 1565 A1/A2 polymorphisms were carried out by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique, plasma tHcy, and folic acid levels were estimated. Results: Fasting plasma total Hcy levels were significantly higher in MI patients than controls (P <0.05), folate levels were significantly lower in MI patients than controls (P <0.05), no significant differences were observed in the MTHFR C677T and GpIIIa genotypes frequencies between MI patients and controls (P > 0.05). The frequency of the MTHFR C allele was 80.6 % and 76 % in MI patients and controls respectively and did not differ significantly between the two groups (P > 0.05). The frequency of risk allele, GpIIIa, PIA2 was significantly higher in MI patients compared to controls (p<0.05), plasma tHcy level was significantly higher and folate level was significantly lower in MI patients carrying MTHFR CC and GPIIIa PIA2A2genotypes. Conclusions: In this population, the both risk alleles of MTHFR and GpIIb/IIIa polymorphisms had no major effect on the MI incidence, they were associated with higher homocysteine levels. A gene-environment interaction might increase the risk indirectly by elevating tHcy, especially when folate intake was low, our findings might support that MTHFR and GpIIb/IIIa polymorphisms as risk factors for MI.



[1]  WHO, 2014;
[2]  WHO and ARE-Ministry of Health & Population: Egypt National Stepwise Survey of on Communicable Diseases Risk Factors 2011-2012.
[3]  Smith SC. Current and future directions of cardiovascular risk prediction. Am J Cardiol. 2006 Jan 16;97(2A):28A-32A.
[4]  Towfighi A, Saver JL, Engelhardt R, Ovbiagele B: Factors associated with the steep increase in late-midlife stroke occurrence among US men. J Stroke Cerebrovasc Dis (2008)17(4):165-168.
[5]  Beard RS, Bearden SE: Vascular complications of cystathionine β-synthase deficiency: Future directions for homocysteine-to-hydrogen sulfide research. Am J Physiol Heart Circ Physiol (2011) 300(1):H13-H26.
Show More References
[6]  William P. Homocysteine and thrombosis: guilt by association? Blood; 2012 119: 2977-2978.
[7]  Holmes MV, Newcombe P, Hubacek JA: Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomized trials. Lancet 2011; 378:584-594.
[8]  Frosst P, Blom MJ, Lios R, Goyette P, Sheppard CA, Matthews RG. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
[9]  Furie B, Furie BC. Mechanisms of Thrombus Formation. N Engl J Med. 2008; 359:938-49.
[10]  Ruggeri ZM, Mendolicchio GL. Adhesion Mechanisms in Platelet Function. Circ Res. 2007; 100:1673-85.
[11]  Bennett JS. Structure and function of the platelet integrin alphaIIbeta3. J Clin Invest. 2005; 115:3363-9.
[12]  Carter AM, Catto AJ, Bamford JM, Grant JP. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke. 1999;30:2606-11.
[13]  Newman PJ, Derbes R, Aster RH. The human platelet alloantigens, PI A1 and PI 2, are associated with a leucine33/proline 33 amino acid polymorphism in membrane glycoprotein IIIa and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-1781.
[14]  European Society of Cardiology. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18: 394-413.
[15]  Bong Su, Dae Ho, Nam K, Jong W: Relationship between Metabolic Syndrome and MTHFR Polymorphism in Colorectal Cancer. J Korean Soc Coloproctol 2011:27(2); 78-82.
[16]  Giuseppe A, Pietro M, Pietro S, defective platelet response to arachidonic acid and thromboxane A2 in subjects with PlA2 polymorphism of b3 subunit (glycoprotein IIIa) British Journal of Haematology, 2000, 110, 911-918.
[17]  Selhub J, Morris M, Jacques P. In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci USA 2007; 104:1995-20000.
[18]  Trinder. P. Determination of blood glucose using an oxidase – peroxidase system with a noncarcinogenic chromogen. Journal of clinical pathology, 1969;19692: 158-161
[19]  Alian. C., Poon. L. and Chan. C. Enzymatic determination of total serum cholesterol. CLIN. CHEM.., 1974; 20 (4): 470-475.
[20]  Siedel. J., Schmuck. R. and Staepels. J. Long-term stable liquid ready to use mono-reagent for the enzymatic assay of serum or plasma triglycerides (GPO-PAP method). AACC Meeting. Abstract 34. Clin Chem., 1993; 39: 1127.
[21]  Lopes-Virella M., Stone R., Ellis S. and Colwell J. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem., 1977; 23:882-884.
[22]  Marniemi J, Maki J, Maatela J, Poor applicability of the Friedewald formula in the assessment of serum LDL cholesterol for clinical purposes. Clin Biochem. 1995; 28(3):285-289.
[23]  Cattaneo M. Hyperhomocysteinemia, atherosclerosis, and thrombosis. Thromb Haemost. 1999; 81:165-76.
[24]  Chua S, Wu CJ, Chang HW, Hang CL, Chen CJ, Yang CH, Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. Int Heart J. 2005; 46: 181-193.
[25]  Pandey U, Kumari R, Nath B. Association of angiotensin- converting enzyme, Methylenetetrahydrofolate reductase and paraoxonase gene polymorphism and coronary artery disease in an Indian Cardiol J. 2011; 18(4):385-394.
[26]  Kuo HK, Sorond FA, Chen JH. The role of homocysteine in multisystem age-related problems: a systematic review. J Gerontol A Biol Sci Med Sci 2005;60:1190-201.
[27]  Jing Ma, Meir J, Charles H. Methylenetetrahydrofolate Reductase Polymorphism, Plasma Folate, Homocysteine, and Risk of Myocardial Infarction in US Physicians Circulation. 1996; 94: 2410-2416.
[28]  Jacques PF, Bostom AG, Williams RR. The relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
[29]  Liang R, Zhou Y, Xie J. Association of C677T gene polymorphisms of methylenetetrahydrofolate reductase and plasma homocysteine level with hyperlipidemia. Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jul;34(8):1195.
[30]  Andreassi MG, Botto N, Cocci F. Methylenetetrahydrofolate': reductase gene C677 T polymorphism, homocysteine, vitamin 8121 folic -acid and DNA damage in coronary artery disease. Hum Genet 2003; 112(2):171-177.
[31]  Qyang B, Fan S, Zhi X, Li Y. Associations of MTHFR Gene Polymorphisms with Hypertension and Hypertension in Pregnancy: A Meta- Analysis from 114 Studies with 15411 Cases and 21970 Controls. PLoS ONE. 2014; 9 (2):e87497.
[32]  Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001; 47:255-262.
[33]  Zheng Y, Tong J, Do X. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 2000; 109: 870-874.
[34]  Weiss EJ, Bray PF, Tayback M. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl J Med 1996;334:1090-1094.
[35]  Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15: 89-93.
[36]  Duan H, Cai Y, and Sun X. Platelet glycoprotein IIb/IIIa polymorphism HPA-3 b/b is associated with increased risk of ischemic stroke in patients under 60 years of age Med Sci Monit. 2012; 18(1).
[37]  Roberta di, Emma M, Matteo N. Hydrogen sulfide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. PNAS. 2013;110 no. 39:15812-15817.
Show Less References